Cleveland BioLabs is getting another $6.6 million in federal defense funding to help pay for studies to measure the effectiveness of the Buffalo drug development company’s anti-radiation sickness drug, U.S. Rep. Brian Higgins, D-Buffalo, announced Monday.
The money is the second major funding that Cleveland BioLabs has received this month from the Defense Department to support key studies it must complete on its Entolimod anti-radiation sickness drug. The company earlier this month won up to $9.2 million in a separate award from the Defense Department.
Cleveland BioLabs believes Entolimod can be an effective treatment for people who have been exposed to potentially lethal doses of radiation, possibly due to a nuclear power plant accident or a terrorist attack. The drug can reduce deaths from potentially lethal exposure to radiation by as much as 40 percent to 60 percent, according to the results of company-funded studies published earlier this month.
The company is seeking approval from the Food and Drug Administration so that Entolimod can be stockpiled for use in an emergency.